{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:08:50Z","timestamp":1779088130375,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2020,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In this issue of\n                    <jats:italic>EMBO Molecular Medicine<\/jats:italic>\n                    , Barbon\n                    <jats:italic>et\u00a0al<\/jats:italic>\n                    describe a new approach to rebalancing coagulation in patients with hemophilia (PWH) through targeted inhibition of anticoagulant antithrombin (AT) (Barbon\n                    <jats:italic>et\u00a0al<\/jats:italic>\n                    , 2020). In contrast to previous studies that used RNA interference (RNAi) therapy to reduce AT levels (Sehgal\n                    <jats:italic>et\u00a0al<\/jats:italic>\n                    , 2015; Pasi\n                    <jats:italic>et\u00a0al<\/jats:italic>\n                    , 2017), the authors utilized llama\u2010derived single\u2010domain antibodies (sdAbs or nanobodies) to inhibit AT activity (Fig\u00a01). These engineered sdAbs successfully restored thrombin generation in hemophilic plasma and corrected bleeding phenotype in a murine hemophilia model. Furthermore, long\u2010term AAV8\u2010mediated hepatic expression of the sdAb was well tolerated and associated with a sustained correction in bleeding in hemophilia A and B mice. Collectively, these exciting data uncover a novel AT\u2010targeting approach that may be useful as an alternative therapy for restoring normal hemostasis in PWH.\n                  <\/jats:p>","DOI":"10.15252\/emmm.202012143","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T09:12:31Z","timestamp":1586250751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antithrombin inhibition using nanobodies to correct bleeding in hemophilia"],"prefix":"10.1038","volume":"12","author":[{"given":"Jamie M","family":"O'Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-3313","authenticated-orcid":false,"given":"James S","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"key":"BFEMMM202012143_CR1","doi-asserted-by":"crossref","first-page":"e11298","DOI":"10.15252\/emmm.201911298","volume":"12","author":"E Barbon","year":"2020","unstructured":"Barbon E, Ayme G, Mohamadi A, Ottavi JF, Kawecki C, Casari C, Verhenne S, Marmier S, van Wittemberghe L, Charles S et\u00a0al (2020) Single\u2010domain antibodies targeting antithrombin reduce bleeding in hemophilia mice with or without inhibitors. EMBO Mol Med 12: e11298","journal-title":"EMBO Mol Med"},{"key":"BFEMMM202012143_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2017-09-743385","volume":"132","author":"MU Callaghan","year":"2018","unstructured":"Callaghan MU, Sidonio R, Pipe SW (2018) Novel therapeutics for hemophilia and other bleeding disorders. Blood 132: 23\u201330","journal-title":"Blood"},{"key":"BFEMMM202012143_CR3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco\u2010Johnson","year":"2007","unstructured":"Manco\u2010Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco\u2010Johnson ML, Funk S, Jacobson L et\u00a0al (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535\u2013544","journal-title":"N Engl J Med"},{"key":"BFEMMM202012143_CR4","unstructured":"Mannucci PM (2002) Hemophilia and related bleeding disorders: a story of dismay and success. Hematology Am Soc Hematol Educ Program 1\u20139"},{"key":"BFEMMM202012143_CR5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","volume":"133","author":"K Nogami","year":"2019","unstructured":"Nogami K, Shima M (2019) New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood 133: 399\u2013406","journal-title":"Blood"},{"key":"BFEMMM202012143_CR6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjh.15872","volume":"186","author":"JS O'Donnell","year":"2019","unstructured":"O'Donnell JS, O'Sullivan JM, Preston RJS (2019) Advances in understanding the molecular mechanisms that maintain normal haemostasis. Br J Haematol 186: 24\u201336","journal-title":"Br J Haematol"},{"key":"BFEMMM202012143_CR7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","volume":"377","author":"KJ Pasi","year":"2017","unstructured":"Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S, Hay CR, Hegemann I et\u00a0al (2017) Targeting of Antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 377: 819\u2013828","journal-title":"N Engl J Med"},{"key":"BFEMMM202012143_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjh.15869","volume":"186","author":"RJS Preston","year":"2019","unstructured":"Preston RJS, O'Sullivan JM, O'Donnell JS (2019) Advances in understanding the molecular mechanisms of venous thrombosis. Br J Haematol 186: 13\u201323","journal-title":"Br J Haematol"},{"key":"BFEMMM202012143_CR9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","volume":"21","author":"A Sehgal","year":"2015","unstructured":"Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, Hettinger J, Carioto M, Jiang Y, Brodsky J et\u00a0al (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis\u00a0in hemophilia. Nat Med, 21: 492\u2013497","journal-title":"Nat Med"},{"key":"BFEMMM202012143_CR10","first-page":"632","volume":"24","author":"T Thorat","year":"2018","unstructured":"Thorat T, Neumann PJ, Chambers JD (2018) Hemophilia burden of disease: a systematic review of the cost\u2010utility literature for hemophilia. J Manag Care Spec Pharm 24: 632\u2013642","journal-title":"J Manag Care Spec Pharm"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202012143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.202012143","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.202012143\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.202012143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.202012143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:31:40Z","timestamp":1779085900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.202012143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,7]]}},"alternative-id":["BFEMMM202012143"],"URL":"https:\/\/doi.org\/10.15252\/emmm.202012143","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,25]]},"assertion":[{"value":"25 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"EMMM202012143"}}